FVR's overview of year 2022 has been published

On March 31st 2023, FVR has published an overview of the founding year of the company. You can access the report by clicking the link below. The report includes the following sections:

‍

• CEO's review
• Review by the Chairperson of the Board of Directors
• FVR in brief
• FVR's role in the value chain
• Company strategy
• Stakeholders
• Corporate governance
• Sustainability
• Examples of research activities in 2022

overview of 2022

‍

FVR – Finnish Vaccine Research became fully operational on September 1, 2022, when the founding organizations, Tampere University Foundation and the Finnish Institute for Health and Welfare (THL), transferred their commercial vaccine research operations, assets, and personnel to the newly established special-assignment company of the Finnish state.

‍

FURTHER INFORMATION

‍

Marikka Nevamäki

Chief Communications and Marketing Officer

marikka.nevamaki(at)fvr.fi